Full Press Release Details
for information purpose only
Soci t Anonyme with a Board
with a share capital of EUR 1,459,512.74
Registered office: 50, rue de Dijon, 21121 Daix
537 530 255 Trade and Companies Registry of Dijon
The shareholders of INVENTIVA (the "Company")
are hereby informed that the Ordinary and Extraordinary general meeting (the "General Meeting") will be held on November 27,
2025 at 9:00 a.m., at the H tel Villa M, 24-30, boulevard Pasteur - 75015 Paris, France.
As a reminder, the agenda of the General Meeting,
unchanged from that published in the notice of meeting published in the Bulletin des Annonces L gales et Obligatoires (BALO) n 126
dated October 20th, 2025, is as follows:
Reading of the report of the Board of Directors;
The draft resolutions to be submitted to the vote
of the General Meeting were published in the meeting notice of the Bulletin des Annonces L gales Obligatoires on October 20,
2025 (bulletin n 126) and remain unchanged.
for information purpose only
In accordance with Article R. 22-10-28 of
the French Commercial Code, shareholders may participate in the General Meeting, if they can prove:
Only shareholders who can prove their status as
such at 0:00 a.m. Paris time on Tuesday, November 25, 2025, under the conditions set out above, may participate in this General
How to participate in the General Meeting
Shareholders have several options for participating
in the General Meeting. They may (1) vote by physically attending the General Meeting or (2) vote remotely or by proxy (a) by
mail or (b) via the Internet.
In accordance with the provisions of Article R.
22-10-28 III of the French Commercial Code, once a shareholder has already cast their vote remotely, sent a proxy, or requested their
admission card or certificate of attendance to attend the General Meeting, he or she may no longer choose another method of participation.
Shareholders wishing to attend the General Meeting
in person must request an admission card as soon as possible in order to receive it in good time, namely:
On the day of the General Meeting, all shareholders
must provide proof of their status during the registration formalities.
for information purpose only
Shareholders who do not attend the General Meeting
may vote remotely or be represented by giving proxy to the Chairperson of the General Meeting, their spouse, their civil union partner,
another shareholder, or any other individual or legal entity of their choice under the conditions set out in Articles L. 225-106 and L.
22-10-39 of the French Commercial Code.
In accordance with the provisions of Article R.
225-79 of the French Commercial Code, the proxy given by a shareholder to be represented must be signed by the shareholder. The shareholder
shall indicate their surname, first name, and domicile, and may designate a proxy, specifying the proxy's surname, first name, and address
or, in the case of a legal entity, the name or business name and registered office. The proxy may not be replaced by another person.
It is specified that, for any proxy without indication
of a proxy holder, the Chairperson of the General Meeting will cast a vote in favor of the adoption of the draft resolutions presented
or approved by the Board of Directors, and a vote against the adoption of all other draft resolutions. To cast any other vote, shareholders
must choose a proxy who agrees to vote in accordance with the instructions of the principal.
For registered shareholders: a postal or
proxy voting form will be sent to them directly. This form should be returned using the prepaid envelope enclosed with the notice of meeting.
For bearer shareholders: as of today, the
postal or proxy voting form can be requested from the intermediaries who manage their securities. All requests must be sent by the relevant
financial intermediary to Soci t G n rale, Service des assembl es, 32, rue du Champ de Tir, CS 30812,
44308 Nantes Cedex 3 no later than six days before the date of the General Meeting (Article R. 225-75 of the French Commercial Code).
The single form for voting by mail or proxy must be accompanied by a certificate of share ownership issued by the financial intermediary,
who must send these documents to Soci t G n rale, Service des assembl es, 32, rue du Champ de Tir,
CS 30812, 44308 Nantes Cedex 3.
In all cases, the duly completed and signed postal
or proxy voting form (accompanied by the certificate of share ownership for bearer shares) must be returned so that it is received by
Soci t G n rale's Shareholders' Meeting Department or the Company no later than three (3) days before
the date of the General Meeting (i.e. Monday, November 24, 2025).
Shareholders may also submit their voting instructions
and appoint or revoke a proxy online prior to the General Meeting on the Votaccess website, under the following conditions:
They may also appoint or revoke a proxy
by sending an email with an electronic signature, obtained from a third-party certifier authorized under the legal and regulatory conditions
in force, to the email address agiva27112025@inventivapharma.com, specifying their surname, first name, address, and Soci t
G n rale ID number for registered shareholders (information available at the top left of their account statement) or their
ID number with their authorized intermediary for nominee-registered shareholders, as well as the surname, first name, and address of the
proxy appointed or revoked;
SGSS is available to answer any questions
shareholders may have from 9 a.m. to 6 p.m. on + 33 (0)2 51 85 67 89;
for information purpose only
Please note that only bearer shareholders
whose account-holding institution has joined Votaccess will be able to vote, appoint or revoke a proxy online.
If the shareholder's account-holding institution
is not connected to Votaccess, notification of the appointment and revocation of a proxy may nevertheless be made electronically in accordance
with the provisions of Articles R. 22-10-24 and R. 225-79 of the French Commercial Code, as follows: by sending an email bearing an electronic
signature, obtained from a third-party certifier authorized under the legal and regulatory conditions in force, to the email address agiva27112025@inventivapharma.com
specifying their surname, first name, address, and full bank details for their securities account, as well as the surname, first name,
and address of the proxy appointed or revoked, and then requesting their authorized intermediary who manages their securities account
to send written confirmation to Soci t G n rale, Service Assembl es.
In order for the appointments or revocations of
proxies, duly signed and completed, to be validly taken into account, they must be received by the Company no later than Monday, November 24,
2025, for notifications made electronically.
The revocation of a proxy must be made in the
same form as that used for its appointment.
The secure Votaccess platform will be open from
Friday, November 7, 2025, at 9:00 a.m. Paris time. The possibility of voting, appointing or revoking a proxy via the Internet
prior to the General Meeting will end on Wednesday, November 26, 2025, at 3 p.m. Paris time. Shareholders are advised not to
wait until the last few days before the General Meeting to enter their instructions.
It should be noted that, in accordance with the
provisions of Article R. 22-10-28 of the French Commercial Code:
Submission of written questions
In accordance with the provisions of Article R.
225-84 of the French Commercial Code, each shareholder shall be entitled to submit written questions of their choice to the Board of Directors
no later than the fourth (4th) business day preceding the date of the General Meeting, i.e., Friday, November 21, 2025.
Requests for the submission of written questions
must be sent to the Company's registered office by registered letter with acknowledgment of receipt. They must be accompanied by a certificate
of registration in the account.
Right of communication
All documents and information provided for in
Article R. 22-10-23 of the French Commercial Code (in particular the text of the draft resolutions submitted to the General Meeting
by the Board of Directors) may be consulted on the Company's website (www.inventivapharma.com) from the twenty-first day preceding the
General Meeting, i.e., Thursday, November 6, 2025.